CL2015001353A1 - Molécula que contiene el dominio de fibronectina de tipo iii (fn3) biespecífico, donde el primer dominio se une al receptor del factor de crecimiento epidérmico (egrf) y el segundo al factor de crecimiento de hepatocitos (c-met); dominio de fn3; polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica que la comprende; y uso para tratar el cáncer. - Google Patents

Molécula que contiene el dominio de fibronectina de tipo iii (fn3) biespecífico, donde el primer dominio se une al receptor del factor de crecimiento epidérmico (egrf) y el segundo al factor de crecimiento de hepatocitos (c-met); dominio de fn3; polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica que la comprende; y uso para tratar el cáncer.

Info

Publication number: CL2015001353A1
Authority: CL; Chile
Prior art keywords: domain; growth factor; egrf; polynucleotide; encodes
Prior art date: 2012-11-21

Application number

CL2015001353A

Other languages

English (en)

Inventor

Sheri Moores

Mark Anderson

Ricardo Attar

Michael Diem

Linus Hyun

Steven Jacobs

Alastair King

Donna Klein

Karyn O'neil

Kristen Picha

Original Assignee

Janssen Biotech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-21

Filing date

2015-05-19

Publication date

2015-10-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50776675&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001353(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-05-19 Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc

2015-10-02 Publication of CL2015001353A1 publication Critical patent/CL2015001353A1/es

Links

102000001301 EGF receptor Human genes 0.000 title 1
108060006698 EGF receptor Proteins 0.000 title 1
102000002090 Fibronectin type III Human genes 0.000 title 1
108050009401 Fibronectin type III Proteins 0.000 title 1
102000003745 Hepatocyte Growth Factor Human genes 0.000 title 1
108090000100 Hepatocyte Growth Factor Proteins 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
210000004027 cell Anatomy 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
102000040430 polynucleotide Human genes 0.000 title 1
108091033319 polynucleotide Proteins 0.000 title 1
239000002157 polynucleotide Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

CL2015001353A 2012-11-21 2015-05-19 Molécula que contiene el dominio de fibronectina de tipo iii (fn3) biespecífico, donde el primer dominio se une al receptor del factor de crecimiento epidérmico (egrf) y el segundo al factor de crecimiento de hepatocitos (c-met); dominio de fn3; polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica que la comprende; y uso para tratar el cáncer. CL2015001353A1 (es)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date
US201261728914P	2012-11-21	2012-11-21
US201261728906P	2012-11-21	2012-11-21
US201261728912P	2012-11-21	2012-11-21
US201361782550P	2013-03-14	2013-03-14
US201361809541P	2013-04-08	2013-04-08

Publications (1)

Publication Number	Publication Date
CL2015001353A1 true CL2015001353A1 (es)	2015-10-02

Family

ID=50776675

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2015001353A CL2015001353A1 (es)	2012-11-21	2015-05-19	Molécula que contiene el dominio de fibronectina de tipo iii (fn3) biespecífico, donde el primer dominio se une al receptor del factor de crecimiento epidérmico (egrf) y el segundo al factor de crecimiento de hepatocitos (c-met); dominio de fn3; polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica que la comprende; y uso para tratar el cáncer.

Country Status (21)

Country	Link
US (4)	US9695228B2 (es)
EP (3)	EP3485901B1 (es)
JP (3)	JP6393270B2 (es)
KR (2)	KR102210196B1 (es)
CN (5)	CN108546300B (es)
AU (3)	AU2013347952B2 (es)
CA (1)	CA2891485A1 (es)
CL (1)	CL2015001353A1 (es)
EA (2)	EA036054B1 (es)
ES (2)	ES2696148T3 (es)
HK (1)	HK1215680A1 (es)
IL (2)	IL238730B (es)
MX (2)	MX369334B (es)
MY (1)	MY176820A (es)
NI (1)	NI201500070A (es)
NZ (1)	NZ708349A (es)
PH (1)	PH12015501134B1 (es)
SG (2)	SG11201503942RA (es)
UA (1)	UA118096C2 (es)
WO (1)	WO2014081944A2 (es)
ZA (1)	ZA201504427B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013177398A2 (en)	2012-05-25	2013-11-28	Janssen Biotech, Inc.	Non-natural consensus albumin binding domains
US9695228B2 (en) *	2012-11-21	2017-07-04	Janssen Biotech, Inc.	EGFR and c-Met fibronectin type III domain binding molecules
MX361088B (es) *	2012-11-21	2018-11-26	Janssen Biotech Inc	Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
CA2892045C (en)	2012-11-21	2022-05-31	Ptc Therapeutics, Inc.	Substituted reverse pyrimidine bmi-1 inhibitors
SI2948559T1 (en) *	2013-01-25	2018-08-31	Janssen Biotech, Inc.	KV1.3 antagonists and application procedures
NZ748260A (en)	2013-08-30	2020-01-31	Ptc Therapeutics Inc	Substituted pyrimidine bmi-1 inhibitors
EA035745B1 (ru)	2013-10-14	2020-08-05	Янссен Байотек, Инк.	Связующие молекулы на основе домена фибронектина типа iii с внедренными остатками цистеина
US10584115B2 (en)	2013-11-21	2020-03-10	Ptc Therapeutics, Inc.	Substituted pyridine and pyrazine BMI-1 inhibitors
CN105085489B (zh)	2014-11-05	2019-03-01	益方生物科技（上海）有限公司	嘧啶或吡啶类化合物、其制备方法和医药用途
WO2016164477A1 (en) *	2015-04-06	2016-10-13	Meso Scale Technologies, Llc.	High throughput system for performing assays using electrochemiluminescence including a consumable shaking apparatus
JP7366518B2 (ja)	2015-05-06	2023-10-23	ヤンセンバイオテツク，インコーポレーテツド	前立腺特異的膜抗原結合フィブロネクチンｉｉｉ型ドメイン
JP7019423B2 (ja)	2015-05-06	2022-02-15	ヤンセンバイオテツク，インコーポレーテツド	前立腺特異的膜抗原（ｐｓｍａ）二重特異性結合剤及びその使用
US20170002058A1 (en) *	2015-06-30	2017-01-05	Regents Of The University Of Minnesota	Compositions and methods that involve protein scaffolds that specifically bind to hepatocyte growth factor receptor
WO2017013136A1 (en) *	2015-07-20	2017-01-26	Scil Proteins Gmbh	Novel binding proteins based on di-ubiquitin muteins and methods for generation
US10336812B2 (en) *	2016-05-10	2019-07-02	Janssen Biotech, Inc.	GDF15 fusion proteins and uses thereof
MX2018013413A (es)	2016-05-26	2019-06-06	Zeno Royalties & Milestones Llc	Compuestos inhibidores de egfr.
MA45186A (fr) *	2016-06-03	2019-04-10	Janssen Biotech Inc	Domaines de fibronectine de type iii se liant à l'albumine sérique
EA201990067A1 (ru) *	2016-06-21	2019-07-31	Янссен Байотек, Инк.	Цистеин-модифицированные связывающие молекулы на основе домена фибронектина iii типа
GB201612520D0 (en) *	2016-07-19	2016-08-31	F-Star Beta Ltd	Binding molecules
TWI782930B (zh)	2016-11-16	2022-11-11	美商再生元醫藥公司	抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US10626165B2 (en)	2016-12-14	2020-04-21	Janssen Biotech, Inc.	CD8a-binding fibronectin type III domains
EP3554535A4 (en)	2016-12-14	2020-10-21	Janssen Biotech, Inc.	PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
WO2018111978A1 (en)	2016-12-14	2018-06-21	Janssen Biotech, Inc.	Cd137 binding fibronectin type iii domains
WO2019018402A2 (en) *	2017-07-17	2019-01-24	Janssen Biotech, Inc.	ANTIGEN-BINDING REGIONS DIRECTED AGAINST FIBRONECTIN TYPE III DOMAINS AND METHODS OF USING THE SAME
US20190184028A1 (en) *	2017-12-14	2019-06-20	Janssen Biotech, Inc.	Targeting with firbronectin type iii like domain molecules
CA3140360A1 (en) *	2019-05-14	2020-11-19	Janssen Biotech, Inc.	Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
KR20220063185A (ko)	2019-09-16	2022-05-17	리제너론 파마슈티칼스 인코포레이티드	면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
US11628222B2 (en)	2019-10-14	2023-04-18	Aro Biotherapeutics Company	CD71 binding fibronectin type III domains
WO2021076574A2 (en)	2019-10-14	2021-04-22	Aro Biotherapeutics Company	Fn3 domain-sirna conjugates and uses thereof
EP4287300A1 (en)	2021-01-29	2023-12-06	Lg Chem, Ltd.	Electrode
WO2024002256A1 (en) *	2022-06-29	2024-01-04	Doma Biopharmaceutical (Suzhou) Co., Ltd.	Anti-egfr/met antibodies and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
CA2067194C (en)	1989-10-05	2003-03-18	Glenn Kawasaki	Cell-free synthesis and isolation of novel genes and polypeptides
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
ES2227512T3 (es)	1991-12-02	2005-04-01	Medical Research Council	Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
WO1994012520A1 (en)	1992-11-20	1994-06-09	Enzon, Inc.	Linker for linked fusion polypeptides
US5686292A (en)	1995-06-02	1997-11-11	Genentech, Inc.	Hepatocyte growth factor receptor antagonist antibodies and uses thereof
EP0985039B1 (en)	1997-06-12	2008-02-20	Novartis International Pharmaceutical Ltd.	Artificial antibody polypeptides
US6472147B1 (en)	1999-05-25	2002-10-29	The Scripps Research Institute	Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20130226834A1 (en)	2000-04-27	2013-08-29	Networth Services, Inc.	Systems and methods for determining the financial status of bonds
CN100497389C (zh) *	2001-06-13	2009-06-10	根马布股份公司	表皮生长因子受体(egfr)的人单克隆抗体
US7595378B2 (en) *	2001-06-13	2009-09-29	Genmab A/S	Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1283053A1 (en)	2001-08-09	2003-02-12	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Inhibitors of HER3 activity
JP4602614B2 (ja)	2001-09-26	2010-12-22	アイシン精機株式会社	自動車用ドア
WO2003037365A1 (en)	2001-11-01	2003-05-08	The Johns Hopkins University	Methods and compositions for treating vascular leak using hepatocyte growth factor
PT1534830E (pt)	2002-09-06	2011-01-31	Isogenica Ltd	Biblioteca de expressão de péptidos in vitro
US7407660B2 (en)	2003-04-16	2008-08-05	Genentech, Inc.	Methods and compositions for selective modulation of vascularization
RS53476B (en) *	2003-07-18	2014-12-31	Amgen Fremont Inc.	Hepatocyte Growth Factor Binders
EP1766068A4 (en)	2004-06-04	2010-03-03	Genentech Inc	EGFR Mutations
CN101636410A (zh) *	2006-11-22	2010-01-27	雅达思	基于酪氨酸激酶受体（包括igf-ir）的工程化蛋白质的靶向治疗剂
DK2076289T3 (da)	2007-04-13	2015-02-09	Dana Farber Cancer Inst Inc	Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider
US20090042906A1 (en)	2007-04-26	2009-02-12	Massachusetts Institute Of Technology	Methods for treating cancers associated with constitutive egfr signaling
WO2009062170A1 (en) *	2007-11-08	2009-05-14	The University Of Chicago	Molecular affinity clamp technology and uses thereof
WO2009085462A1 (en)	2007-12-19	2009-07-09	Centocor, Inc.	Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
WO2009085468A2 (en)	2007-12-19	2009-07-09	Centocor, Inc.	Engineered phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pix of m13 phage
WO2009102421A2 (en)	2008-02-14	2009-08-20	Bristol-Myers Squibb Company	Targeted therapeutics based on engineered proteins that bind egfr
EP2257293A2 (en)	2008-03-06	2010-12-08	Genentech, Inc.	Combination therapy with c-met and egfr antagonists
PE20091827A1 (es)	2008-04-11	2009-11-20	Galaxy Biotech Llc	Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer
WO2009133208A1 (en) *	2008-05-02	2009-11-05	Novartis Ag	Improved fibronectin-based binding molecules and uses thereof
JP2011520961A (ja)	2008-05-22	2011-07-21	ブリストル−マイヤーズスクイブカンパニー	多価フィブロネクチンをベースとする足場ドメインタンパク質
CA2738583A1 (en)	2008-10-01	2010-04-08	Ludwig Institute For Cancer Research	Methods for the treatment of cancer
PL2356269T3 (pl) *	2008-10-31	2016-12-30		Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania
TWI496582B (zh) *	2008-11-24	2015-08-21	必治妥美雅史谷比公司	雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US8545839B2 (en) *	2008-12-02	2013-10-01	Pierre Fabre Medicament	Anti-c-Met antibody
CN102596992B (zh) *	2009-02-12	2015-09-09	詹森生物科技公司	基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
MX2011010158A (es)	2009-04-07	2011-10-17	Roche Glycart Ag	Anticuerpos biespecificos anti-erbb-2/anti-c-met.
AU2011226103C1 (en)	2010-03-10	2016-04-28	Genmab A/S	Monoclonal antibodies against c-Met
WO2011130324A1 (en) *	2010-04-13	2011-10-20	Medimmune, Llc	Fibronectin type iii domain-based multimeric scaffolds
SG184427A1 (en)	2010-04-20	2012-11-29	Genmab As	Heterodimeric antibody fc-containing proteins and methods for production thereof
RU2624027C2 (ru) *	2010-04-23	2017-06-30	Дженентек, Инк.	Получение гетеромультимерных белков
EP3569256B1 (en)	2010-04-30	2022-06-15	Janssen Biotech, Inc.	Stabilized fibronectin domain compositions, methods and uses
EP2621953B1 (en)	2010-09-30	2017-04-05	Ablynx N.V.	Biological materials related to c-met
EP3540100B8 (en)	2011-09-27	2022-11-02	Janssen Biotech, Inc.	Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
WO2013177398A2 (en)	2012-05-25	2013-11-28	Janssen Biotech, Inc.	Non-natural consensus albumin binding domains
US9695228B2 (en) *	2012-11-21	2017-07-04	Janssen Biotech, Inc.	EGFR and c-Met fibronectin type III domain binding molecules
MX361088B (es) *	2012-11-21	2018-11-26	Janssen Biotech Inc	Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
EA035745B1 (ru) *	2013-10-14	2020-08-05	Янссен Байотек, Инк.	Связующие молекулы на основе домена фибронектина типа iii с внедренными остатками цистеина

2013
- 2013-11-20 US US14/085,340 patent/US9695228B2/en active Active
- 2013-11-21 EP EP18197990.7A patent/EP3485901B1/en active Active
- 2013-11-21 MY MYPI2015701606A patent/MY176820A/en unknown
- 2013-11-21 SG SG11201503942RA patent/SG11201503942RA/en unknown
- 2013-11-21 ES ES13856353T patent/ES2696148T3/es active Active
- 2013-11-21 EP EP13856353.1A patent/EP2922566B1/en active Active
- 2013-11-21 KR KR1020157016173A patent/KR102210196B1/ko active IP Right Grant
- 2013-11-21 NZ NZ708349A patent/NZ708349A/en unknown
- 2013-11-21 CN CN201810391538.8A patent/CN108546300B/zh active Active
- 2013-11-21 EA EA201791577A patent/EA036054B1/ru unknown
- 2013-11-21 CN CN201610885343.XA patent/CN106977606B/zh active Active
- 2013-11-21 JP JP2015544132A patent/JP6393270B2/ja active Active
- 2013-11-21 KR KR1020217002591A patent/KR20210013324A/ko not_active Application Discontinuation
- 2013-11-21 EP EP21201889.9A patent/EP4023670A1/en not_active Withdrawn
- 2013-11-21 EA EA201590998A patent/EA035559B1/ru unknown
- 2013-11-21 CN CN202110937807.8A patent/CN113667020A/zh active Pending
- 2013-11-21 SG SG10201707488TA patent/SG10201707488TA/en unknown
- 2013-11-21 US US14/086,250 patent/US9725497B2/en active Active
- 2013-11-21 AU AU2013347952A patent/AU2013347952B2/en active Active
- 2013-11-21 WO PCT/US2013/071267 patent/WO2014081944A2/en active Application Filing
- 2013-11-21 CA CA2891485A patent/CA2891485A1/en active Pending
- 2013-11-21 UA UAA201506065A patent/UA118096C2/uk unknown
- 2013-11-21 CN CN201380071078.6A patent/CN104955473B/zh active Active
- 2013-11-21 CN CN201610884250.5A patent/CN107098975B/zh active Active
- 2013-11-21 MX MX2015006386A patent/MX369334B/es active IP Right Grant
- 2013-11-21 ES ES18197990T patent/ES2899292T3/es active Active
2015
- 2015-05-10 IL IL238730A patent/IL238730B/en active IP Right Grant
- 2015-05-19 CL CL2015001353A patent/CL2015001353A1/es unknown
- 2015-05-20 NI NI201500070A patent/NI201500070A/es unknown
- 2015-05-20 MX MX2019013117A patent/MX2019013117A/es unknown
- 2015-05-21 PH PH12015501134A patent/PH12015501134B1/en unknown
- 2015-06-19 ZA ZA2015/04427A patent/ZA201504427B/en unknown
2016
- 2016-03-30 HK HK16103676.7A patent/HK1215680A1/zh unknown
2017
- 2017-06-29 US US15/637,276 patent/US10954284B2/en active Active
2018
- 2018-08-24 JP JP2018157120A patent/JP7015223B2/ja active Active
- 2018-10-04 AU AU2018241106A patent/AU2018241106B2/en active Active
2019
- 2019-11-24 IL IL270852A patent/IL270852B/en active IP Right Grant
2020
- 2020-11-13 AU AU2020267284A patent/AU2020267284B2/en active Active
2021
- 2021-02-12 US US17/174,524 patent/US20210206825A1/en active Pending
- 2021-09-24 JP JP2021155530A patent/JP2022008534A/ja active Pending

Also Published As

Publication number	Publication date
EP3485901A1 (en)	2019-05-22
EA036054B1 (ru)	2020-09-21
SG10201707488TA (en)	2017-10-30
AU2020267284B2 (en)	2022-03-31
US20210206825A1 (en)	2021-07-08
ES2899292T3 (es)	2022-03-10
EP3485901B1 (en)	2021-10-13
JP2022008534A (ja)	2022-01-13
AU2018241106B2 (en)	2020-08-20
NI201500070A (es)	2015-09-21
HK1215680A1 (zh)	2016-09-09
US20140155325A1 (en)	2014-06-05
US9695228B2 (en)	2017-07-04
MY176820A (en)	2020-08-21
NZ708349A (en)	2020-10-30
UA118096C2 (uk)	2018-11-26
IL270852B (en)	2020-09-30
AU2018241106A1 (en)	2018-10-25
KR20150087340A (ko)	2015-07-29
CN107098975B (zh)	2021-11-05
CN104955473B (zh)	2018-05-18
PH12015501134A1 (en)	2015-08-17
EA201791577A1 (ru)	2017-11-30
EP2922566B1 (en)	2018-10-03
EP2922566A2 (en)	2015-09-30
JP6393270B2 (ja)	2018-09-19
AU2013347952A1 (en)	2015-05-28
KR102210196B1 (ko)	2021-02-01
SG11201503942RA (en)	2015-06-29
IL238730A0 (en)	2015-06-30
MX2019013117A (es)	2019-12-16
AU2020267284A1 (en)	2020-12-10
IL270852A (en)	2020-01-30
PH12015501134B1 (en)	2015-08-17
ES2696148T3 (es)	2019-01-14
NZ748444A (en)	2020-10-30
CN113667020A (zh)	2021-11-19
ZA201504427B (en)	2017-11-29
US20140155326A1 (en)	2014-06-05
US9725497B2 (en)	2017-08-08
EP2922566A4 (en)	2016-10-26
EA201590998A1 (ru)	2016-02-29
JP2019033748A (ja)	2019-03-07
CN108546300B (zh)	2022-03-15
CN106977606A (zh)	2017-07-25
WO2014081944A9 (en)	2015-09-17
CN108546300A (zh)	2018-09-18
US20170305997A1 (en)	2017-10-26
JP2016504291A (ja)	2016-02-12
CN107098975A (zh)	2017-08-29
WO2014081944A3 (en)	2014-07-17
CN106977606B (zh)	2021-08-27
AU2013347952B2 (en)	2018-07-12
US10954284B2 (en)	2021-03-23
CA2891485A1 (en)	2014-05-30
IL238730B (en)	2019-12-31
JP7015223B2 (ja)	2022-02-02
EA035559B1 (ru)	2020-07-07
MX2015006386A (es)	2015-12-03
MX369334B (es)	2019-11-05
KR20210013324A (ko)	2021-02-03
WO2014081944A2 (en)	2014-05-30
CN104955473A (zh)	2015-09-30
EP4023670A1 (en)	2022-07-06

Publication	Publication Date	Title
CL2015001353A1 (es)	2015-10-02	Molécula que contiene el dominio de fibronectina de tipo iii (fn3) biespecífico, donde el primer dominio se une al receptor del factor de crecimiento epidérmico (egrf) y el segundo al factor de crecimiento de hepatocitos (c-met); dominio de fn3; polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica que la comprende; y uso para tratar el cáncer.
BR112016027585A2 (pt)	2018-01-30	construções de anticorpo multiespecíficas
BR112016030424A2 (pt)	2017-10-24	construções de anticorpo multiespecíficas
UY35456A (es)	2014-05-30	Moléculas de unión para bcma y cd3
CL2014003465A1 (es)	2015-02-27	Anticuerpo que se une al receptor del factor de crecimiento epidérmico humano dimérico (hegfr) ; composición farmacéutica que lo comprende; y uso para tratar el cáncer.
CL2015001356A1 (es)	2015-11-06	Anticuerpos bioespecificos egfr/c-met
MX2020012240A (es)	2021-02-22	Agentes de ligacion agonistas del receptor tnf.
CL2014003227A1 (es)	2015-02-06	Compuestos derivados de imidazol condensados, como moduladores de la actividad del receptor del factor de crecimiento epidermico (egfr); composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de cancer colorrectal, de mama, de pancreas, de ovario, entre otros.
CL2015000094A1 (es)	2015-06-19	Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide.
ECSP14004893A (es)	2015-06-30	Moléculas de unión para bcma y cd3
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
MX2016002571A (es)	2016-06-14	Regulador de ph de transduccion.
EA201591748A1 (ru)	2016-02-29	Модуляторы p2x7
BR112016015677A2 (pt)	2017-10-03	Moléculas de anticorpo isoladas capazes de se ligarem à pd-1 humana, bem como seu método de produção e seu uso, composições farmacêuticas, ácido nucleico, vetor de expressão, célula hospedeira, e método para detecção de pd-1 em uma amostra biológica
AR090903A1 (es)	2014-12-17	Anticuerpos e inmunoconjugados anti-pmel17
CL2014000631A1 (es)	2014-09-26	Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
AR095596A1 (es)	2015-10-28	Moléculas de unión de cadena única comprendiendo n-terminal abp
CL2015000711A1 (es)	2015-09-04	Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.
UY35013A (es)	2014-03-31	Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos
CL2012002189A1 (es)	2012-11-23	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
AR091024A1 (es)	2014-12-30	Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos
CL2014001858A1 (es)	2014-09-26	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CL2011002417A1 (es)	2012-03-30	Anticuerpo especifico para fcrh5, receptor de superficie celular con homologia con las familias del receptor fc; anticuerpo anti-fcrh5 humanizado; polinucleotido que lo codifica; vector; celular huesped; metodo de obtencion; inmunoconjugado; composicion farmaceutica; y su uso para tratar cancer.
EA201690461A1 (ru)	2016-11-30	Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
CL2011002660A1 (es)	2012-05-25	Anticuerpo anti-receptor de activinas tipo iib (anti-actr-iib); secuencia de polinucleotidos aislados que codifica dicho anticuerpo; vector, celula huesped; composicion farmaceutica; uso para tratar transtornos musculo esqueleticos.